Determination of Optimized Oxygen Partial Pressure to Maximize the Liver Regenerative Potential of the Secretome Obtained from Adipose-derived Stem Cells
Overview
Authors
Affiliations
Background: A hypoxic-preconditioned secretome from stem cells reportedly promotes the functional and regenerative capacity of the liver more effectively than a control secretome. However, the optimum oxygen partial pressure (pO) in the cell culture system that maximizes the therapeutic potential of the secretome has not yet been determined.
Methods: We first determined the cellular alterations in adipose tissue-derived stem cells (ASCs) cultured under different pO (21%, 10%, 5%, and 1%). Subsequently, partially hepatectomized mice were injected with the secretome of ASCs cultured under different pO, and then sera and liver specimens were obtained for analyses.
Results: Of all AML12 cells cultured under different pO, the AML12 cells cultured under 1% pO showed the highest mRNA expression of proliferation-associated markers (IL-6, HGF, and VEGF). In the cell proliferation assay, the AML12 cells cultured with the secretome of 1% pO showed the highest cell proliferation, followed by the cells cultured with the secretome of 21%, 10%, and 5% pO, in that order. When injected into the partially hepatectomized mice, the 1% pO secretome most significantly increased the number of Ki67-positive cells, reduced serum levels of proinflammatory mediators (IL-6 and TNF-α), and reduced serum levels of liver transaminases. In addition, analysis of the liver specimens indicated that injection with the 1% pO secretome maximized the expression of the intermediate molecules of the PIP3/Akt and IL-6/STAT3 signaling pathways, all of which are known to promote liver regeneration.
Conclusions: The data of this study suggest that the secretome of ASCs cultured under 1% pO has the highest liver reparative and regenerative potential of all the secretomes tested here.
Labarre K, Grathwol P, Zimmermann G Bone Rep. 2024; 24:101820.
PMID: 39691445 PMC: 11650265. DOI: 10.1016/j.bonr.2024.101820.
Zheng L, Gong H, Zhang J, Guo L, Zhai Z, Xia S Front Bioeng Biotechnol. 2023; 11:1322514.
PMID: 38155924 PMC: 10753838. DOI: 10.3389/fbioe.2023.1322514.
Zhao Y, Fu L, Chen J, Zhou J, Tian C, Zhou D J Oncol. 2022; 2022:8802453.
PMID: 36185619 PMC: 9519309. DOI: 10.1155/2022/8802453.
Hepatocyte and mesenchymal stem cell co-transplantation in rats with acute liver failure.
Ho C, Chen Y, Chien C, Ho S, Chen H, Hu R Korean J Transplant. 2022; 34(2):100-108.
PMID: 35769351 PMC: 9187042. DOI: 10.4285/kjt.2020.34.2.100.
Hazrati A, Malekpour K, Soudi S, Hashemi S Front Immunol. 2022; 13:865888.
PMID: 35464407 PMC: 9021384. DOI: 10.3389/fimmu.2022.865888.